Table of Contents
Overview
New York, NY – Jan 06, 2026 – Global Myomectomy Market size is expected to be worth around USD 1688.3 Million by 2033 from USD 720.1 Million in 2023, growing at a CAGR of 8.9% during the forecast period from 2024 to 2033.
Myomectomy is a well-established surgical procedure used for the removal of uterine fibroids while preserving the uterus. Uterine fibroids are non-cancerous growths that commonly affect women of reproductive age and may lead to symptoms such as heavy menstrual bleeding, pelvic pain, pressure symptoms, and fertility-related concerns. Myomectomy is widely recommended for patients who wish to maintain reproductive potential or avoid hysterectomy.
The procedure involves the selective excision of fibroids from the uterine wall, with careful reconstruction of uterine tissue to restore normal anatomy and function. Depending on the size, number, and location of fibroids, myomectomy may be performed through different surgical approaches, including abdominal (open), laparoscopic, robotic-assisted, or hysteroscopic techniques. The choice of approach is determined by clinical evaluation and imaging findings, ensuring optimal outcomes and patient safety.
Clinical evidence indicates that myomectomy is effective in reducing fibroid-related symptoms and improving quality of life. In patients experiencing infertility associated with fibroids, the procedure has been shown to improve pregnancy outcomes in appropriately selected cases. Advances in minimally invasive techniques have further reduced recovery time, blood loss, and hospital stay.
Overall, myomectomy remains a standard and reliable treatment option for symptomatic uterine fibroids. Ongoing improvements in surgical technology and perioperative care continue to enhance clinical results, supporting its role as a key fertility-preserving intervention in gynecological practice.
Key Takeaways
- Market Size: The myomectomy market is projected to reach approximately USD 1,688.3 million by 2033, rising from USD 720.1 million in 2023.
- Market Growth: The market is expected to expand at a compound annual growth rate (CAGR) of 8.9% during the forecast period from 2024 to 2033.
- Type Analysis: In 2023, abdominal myomectomy emerged as the leading procedure type, accounting for 38.41% of the total market share.
- Product Analysis: Laparoscopic sealers held a significant position in 2023, capturing 25.16% of the market share.
- End-Use Analysis: Hospitals and clinics represented the dominant end-use segment in 2023, with a market share of 41.57%.
- Regional Analysis: North America led the global myomectomy market in 2023, contributing 43.30% of total revenue.
- Technological Innovation: The increasing adoption of minimally invasive techniques, including laparoscopic and robotic-assisted procedures, is transforming the market. Advanced systems and precision surgical instruments are improving clinical outcomes and reducing patient recovery time.
- Opportunities: Growth prospects are supported by emerging economies, continuous advancements in robotic surgery, and increasing government initiatives aimed at improving women’s healthcare infrastructure.
Regional Analysis
In 2023, North America accounted for a substantial 43.30% share of the global myomectomy market, highlighting its dominant position within the industry. This leadership is primarily supported by the region’s well-developed healthcare infrastructure, widespread access to advanced medical facilities, and the presence of experienced and highly trained surgical specialists. In addition, the relatively high incidence of uterine fibroids across the population continues to generate strong procedural demand.
The region’s early adoption of advanced and minimally invasive surgical techniques has further strengthened market growth. Continuous investments in healthcare innovation, combined with favorable reimbursement frameworks, have improved patient access to myomectomy procedures. Moreover, increased disease awareness and targeted public health initiatives focused on early diagnosis and effective management of uterine fibroids have contributed to higher treatment rates.
Take advantage of our unbeatable offer - buy now!
Collectively, these structural and policy-driven factors reinforce North America’s leadership in the global myomectomy market. The region is expected to maintain its strong market presence, supported by ongoing technological advancements and a sustained focus on improving women’s health outcomes.
Emerging Trends
- Growing Adoption of Minimally Invasive Myomectomy (MIM): The use of minimally invasive approaches has increased steadily over the past decade. Laparoscopic myomectomy adoption rose from 6.0% in 2009 to 24.9% in 2019, while robotic-assisted procedures increased from 3.6% to 8.5% over the same period. This shift has been driven by clinical advantages such as reduced intraoperative blood loss, shorter hospitalization, and faster postoperative recovery.
- Advances in Robotic-Assisted Surgery: Robotic-assisted laparoscopic myomectomy has gained acceptance as an alternative to open surgery. Clinical outcomes indicate shorter hospital stays, reduced postoperative pain, and quicker resumption of daily activities. Despite these benefits, higher procedural costs and longer operative times continue to be key considerations influencing adoption.
- Demographic Patterns and Fertility Preservation: Women aged 31–40 years represent the largest share of myomectomy patients, accounting for approximately 55.9% of procedures. This age distribution highlights the continued importance of uterine- and fertility-preserving surgical options in clinical decision-making.
Use Cases
- Disease Burden and Clinical Need: Uterine fibroids remain a highly prevalent gynecological condition, with reported incidence rates of 63.5 per 10,000 person-years based on over 16,000 newly identified cases. Myomectomy continues to serve as a primary surgical treatment for symptomatic fibroids, particularly among women seeking to preserve reproductive potential.
- Safety and Risk Profile: Large-scale analyses involving more than 23,500 women aged 15–55 years indicate that myomectomy is associated with a low mortality rate of 1.3 per 10,000 patients. The incidence of major thromboembolic complications, including venous thromboembolism, deep vein thrombosis, and pulmonary embolism, remains low, supporting the overall safety of the procedure.
- Postoperative and Functional Outcomes: Comparative evidence suggests that patients undergoing robotic-assisted laparoscopic myomectomy experience shorter hospital stays, averaging 1.5 days compared with 2.7 days for abdominal myomectomy, along with faster return to work, with 85.7% resuming employment within one month. However, robotic procedures are typically associated with longer operative times and may carry a higher likelihood of residual fibroid presence.
Frequently Asked Questions on Myomectomy
- Who is an ideal candidate for myomectomy?
Myomectomy is typically recommended for women with symptomatic uterine fibroids causing pain, heavy menstrual bleeding, or infertility. It is preferred when uterine preservation is clinically important and fibroid size or location permits surgical removal. - What are the different types of myomectomy procedures?
Myomectomy can be performed through abdominal, laparoscopic, robotic-assisted, or hysteroscopic approaches. The choice of technique is determined by fibroid size, number, location, patient health status, and surgeon expertise. - What is the recovery period after myomectomy?
Recovery time varies by surgical approach. Minimally invasive myomectomy generally requires two to four weeks, while open abdominal myomectomy may require four to six weeks for full recovery and return to normal activities. - How is minimally invasive surgery impacting the myomectomy market?
Minimally invasive techniques, including laparoscopic and robotic-assisted myomectomy, are expanding market adoption due to shorter hospital stays, reduced complications, faster recovery, and improved clinical outcomes compared to conventional open surgery. - Which regions dominate the global myomectomy market?
North America and Europe currently dominate the market due to advanced healthcare infrastructure, high diagnosis rates, and widespread adoption of surgical technologies. Asia-Pacific is expected to witness faster growth due to improving healthcare access. - What role do hospitals and specialty clinics play in the market?
Hospitals and specialty gynecology clinics represent the primary end users, supported by skilled surgeons and advanced equipment. The shift toward outpatient surgical centers is also contributing to procedural volume growth. - What is the future outlook of the myomectomy market?
The myomectomy market is expected to grow steadily, supported by innovation in surgical devices, increasing preference for fertility-preserving treatments, and expanding healthcare investments, particularly in emerging economies with unmet gynecological care needs.
Conclusion
In conclusion, myomectomy continues to represent a clinically effective and economically expanding solution for the management of symptomatic uterine fibroids. Its strong adoption is driven by the growing preference for fertility-preserving treatments, high disease prevalence, and continuous advancements in minimally invasive and robotic-assisted surgical technologies.
Favorable safety outcomes, improved quality of life, and positive reproductive results further reinforce its clinical value. From a market perspective, sustained growth is supported by robust healthcare infrastructure in developed regions and rising investments in women’s health across emerging economies, positioning myomectomy as a key procedure within modern gynecological care.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
